Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP13758	Chaetocin
BP13758	Chaetocin, a natural product from Chaetomium species, is a histone methyltransferase inhibitor with IC50 of 0.8 μM, 2.5 μM and 3 μM for dSU(VAR)3-9, mouse G9a and Neurospora crassa DIM5, respectively.
BP13757	CG347B
BP13757	CG347B is a selective inhibitor of HDAC6.
BP13756	Ivaltinostat
BP13756	CG-200745 is a potent inhibitor of HDAC. CG200745 induces apoptosis and also inhibits the deacetylation of histone H3 and tubulin.
BP13755	CF53
BP13755	CF53 is a highly potent, selective, and orally active inhibitor of BET protein (Ki: <1 nM, Kd: 2.2 nM, IC50: 2 nM for BRD4 BD1).
BP13754	Cerdulatinib
BP13754	Cerdulatinib is an novel oral dual Syk/JAK inhibitor.
BP13753	Cercosporin
BP13753	Cercosporin is produced by a plant pathogen, Cercosporakikuchii, and the elsinochromes. Cercosporin is a potent photosensitizer with a short activation wavelength. Cercosporin contains the perylene quinone structural features necessary for PKC activity (IC50: 0.6-1.3 μM).
BP13752	Cedrusin
BP13752	Cedrusin shows a cytotoxic effect on A375 and HeLa cells.
BP13751	Inobrodib
BP13751	CBP-IN-1 is a potent inhibitor of p300/CBP bromodomain.
BP13750	CBP/EP300-IN-1
BP13750	CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
BP13749	CAY10603
BP13749	CAY10603 is a potent and selective inhibitor of HDAC6.
BP13748	CAY10602
BP13748	CAY10602 is a SIRT1 activator. CAY10602 was derived from high throughput screening for compounds that increase SIRT1-mediated deacetylation of a SIRT1-specific substrate. Functional assays show that CAY10602 dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells, with approximately 75% inhibition achieved at 60 μM, without cytotoxicity.
BP13747	C-82
BP13747	C-82 is a specific CBP/β-catenin antagonist. It inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.
BP13746	C-7280948
BP13746	C-7280948 is a PRMT1 inhibitor.
BP13745	BYK204165
BP13745	BYK204165 is a potent PARP inhibitor (PARP1; IC50 = 44.67 nM for human recombinant PARP1 in an enzyme assay)
BP13744	BVT948
BP13744	BVT948 is a protein tyrosine phosphatase (PTP) inhibitor.It can also inhibit lysine methyltransferase SETD8 (KMT5A) and several cytochrome P450 (P450) isoforms.
BP13743	Buformin hydrochloride
BP13743	Buformin hydrochloride is a potent AMPK activator,an oral antidiabetic drug of the biguanide class. Buformin delays the absorption of glucose from the gastrointestinal tract increases insulin sensitivity and glucose uptake into cells and inhibits synthesis of glucose by the liver. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels.
BP13742	Bufexamac
BP13742	Bufexamac is a COX inhibitor for IFN-α release with anti-inflammatory, analgesic, and antipyretic action.
BP13741	Bryostatin 1
BP13741	Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a CNS)permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein (Kis: 8.07 nM and 0.45 nM).
BP13740	BRM/BRG1 ATP Inhibitor-2
BP13740	BRM/BRG1 ATP Inhibitor-2 is an inhibitor of BRG1/BRM ATPase and can be used in studies about the treatment of BAF-related disorders.
BP13739	BRM/BRG1 ATP Inhibitor-1
BP13739	BRM/BRG1 ATP Inhibitor-1 is an allosteric dual Brahma homolog (BRM)/SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and BRG1/SMARCA4 ATPase activity inhibitor (IC50s<0.005 μM).